Eli Lilly and Company (NYSE:LLY) Stock Holdings Lifted by Grantham Mayo Van Otterloo & Co. LLC

Grantham Mayo Van Otterloo & Co. LLC raised its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 1.5% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 435,232 shares of the company's stock after purchasing an additional 6,368 shares during the quarter. Eli Lilly and Company accounts for 1.1% of Grantham Mayo Van Otterloo & Co. LLC's holdings, making the stock its 29th largest holding. Grantham Mayo Van Otterloo & Co. LLC's holdings in Eli Lilly and Company were worth $335,998,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of LLY. Highline Wealth Partners LLC boosted its holdings in Eli Lilly and Company by 80.0% during the 4th quarter. Highline Wealth Partners LLC now owns 45 shares of the company's stock valued at $35,000 after acquiring an additional 20 shares during the period. Kovitz Investment Group Partners LLC increased its position in shares of Eli Lilly and Company by 117.1% during the third quarter. Kovitz Investment Group Partners LLC now owns 46,132 shares of the company's stock worth $41,000 after acquiring an additional 24,879 shares during the period. FPC Investment Advisory Inc. increased its holdings in Eli Lilly and Company by 358.3% during the 4th quarter. FPC Investment Advisory Inc. now owns 55 shares of the company's stock worth $45,000 after purchasing an additional 43 shares during the period. Prudent Man Investment Management Inc. acquired a new stake in Eli Lilly and Company in the fourth quarter valued at approximately $48,000. Finally, Compass Financial Services Inc acquired a new stake in shares of Eli Lilly and Company in the 4th quarter valued at $50,000. Institutional investors and hedge funds own 82.53% of the company's stock.

Remove Ads

Eli Lilly and Company Stock Performance

NYSE:LLY traded down $8.85 during midday trading on Tuesday, reaching $714.88. The stock had a trading volume of 2,938,936 shares, compared to its average volume of 3,337,692. Eli Lilly and Company has a 12-month low of $677.09 and a 12-month high of $972.53. The stock has a market cap of $677.83 billion, a P/E ratio of 60.99, a P/E/G ratio of 1.40 and a beta of 0.51. The company has a quick ratio of 0.97, a current ratio of 1.15 and a debt-to-equity ratio of 2.00. The firm has a fifty day simple moving average of $846.64 and a two-hundred day simple moving average of $830.05.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The company reported $5.32 EPS for the quarter, missing analysts' consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. On average, equities analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company declared that its board has approved a share repurchase program on Monday, December 9th that permits the company to buyback $15.00 billion in outstanding shares. This buyback authorization permits the company to repurchase up to 2% of its shares through open market purchases. Shares buyback programs are usually an indication that the company's management believes its stock is undervalued.

Insider Buying and Selling at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 1,000 shares of the stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $818.24, for a total transaction of $818,240.00. Following the transaction, the chief accounting officer now directly owns 5,840 shares in the company, valued at $4,778,521.60. This represents a 14.62 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 0.13% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on LLY shares. Bank of America reissued a "buy" rating and issued a $997.00 target price on shares of Eli Lilly and Company in a report on Tuesday, December 10th. Wells Fargo & Company boosted their target price on Eli Lilly and Company from $970.00 to $1,100.00 and gave the stock an "overweight" rating in a research note on Wednesday, March 5th. StockNews.com upgraded shares of Eli Lilly and Company from a "hold" rating to a "buy" rating in a research note on Friday, February 7th. Leerink Partners set a $950.00 price objective on shares of Eli Lilly and Company in a report on Friday, January 17th. Finally, Citigroup lowered their target price on shares of Eli Lilly and Company from $1,250.00 to $1,190.00 and set a "buy" rating for the company in a report on Tuesday, January 28th. Two research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $1,018.89.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.